Effect of a selective MAO-A inhibitor (Ro 41-1049) on striatal L-dopa and dopamine metabolism: An in vivo study

T. Brannan, A. Prikhojan, M. D. Yahr

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

We administered Ro 41-1049, an inhibitor of the enzyme monoamine oxidase type A (MAO-A) to rats and monitored extracellular catecholamine levels in the corpus striatum before and after the intraperitoneal (IP) administration of a bolus of L-dopa. Acute administration of Ro 41-1049 (1-50 mg/kg IP) produced a dose-dependent decrease in basal levels of the dopamine metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) and an increase in basal levels of dopamine. In rats treated with Ro 41-1049 (20 mg/kg IP), L-dopa administration (100 mg/kg IP) produced a greater increase in striatal levels of dopamine than it did in controls, while DOPAC and HVA formation was attenuated. We conclude that inhibition of central MAO-A activity promotes synaptic accumulation of dopamine following administration of pharmacological doses of L-dopa.

Original languageEnglish
Pages (from-to)99-105
Number of pages7
JournalJournal of Neural Transmission - Parkinson's Disease and Dementia Section
Volume8
Issue number1-2
DOIs
StatePublished - Feb 1994

Keywords

  • MAO-A
  • Monoamine oxidase type A
  • Parkinson's disease
  • cerebral microdialysis
  • depression
  • dopamine

Fingerprint

Dive into the research topics of 'Effect of a selective MAO-A inhibitor (Ro 41-1049) on striatal L-dopa and dopamine metabolism: An in vivo study'. Together they form a unique fingerprint.

Cite this